FENC
Fennec Pharmaceuticals Inc.
FENC's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over FENC overall, supported by lower modeled downside and stronger valuation.
FENC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Unavailable |
FENC's revenue, profitability and cash flow are currently healthy. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
FENC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $10.90 | — |
| Current | 1,090x | $10.90 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
FENC has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
FENC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for FENC, with profitability improving. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
FENC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.68 | +6660% |
| Q3 2026 | $0.01 | +$0.25 |
| Q2 2026 | -$0.13 | +$0.30 |
| Q1 2026 | -$0.29 | +$0.23 |
| Q4 2025 | -$0.34 | -$0.27 |
| Q3 2025 | -$0.24 | +$0.83 |
| Q2 2025 | -$0.43 | +$0.50 |
| Q1 2025 | -$0.52 | +$0.42 |
| Q4 2024 | -$0.07 | +$1.51 |
FENC has returned to profit: it earned $0.01 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over FENC on earnings, with more consistent year-over-year improvement.
FENC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.6M | +57% |
| Q2 2026 | $17.9M | +85% |
| Q1 2026 | $15.1M | +73% |
| Q4 2025 | $13.8M | +74% |
| Q3 2025 | $12.5M | +79% |
| Q2 2025 | $9.7M | +33% |
| Q1 2025 | $8.8M | -66% |
| Q4 2024 | $7.9M | -20% |
FENC's revenue is recovering but still below its 2024 peak: $20M last quarter, up 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +25 points |
| Q2 2026 | 9.7% | +38 points |
| Q1 2026 | -0.8% | +8.4 points |
| Q4 2025 | -19% | -6.8 points |
| Q3 2025 | -1.5% | +73 points |
| Q2 2025 | -28% | +41 points |
| Q1 2025 | -9.2% | -63 points |
| Q4 2024 | -12% | +6.5 points |
FENC's operating margin was 24% last quarter, up 25 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over FENC on profitability, with a higher operating margin.
FENC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.7M | +348% |
| Q2 2026 | $50K | +$3.7M |
| Q1 2026 | $2.4M | +$6.7M |
| Q4 2025 | -$6M | -$4.5M |
| Q3 2025 | $1.5M | +$3.7M |
| Q2 2025 | -$3.7M | +$4.7M |
| Q1 2025 | -$4.3M | -111% |
| Q4 2024 | -$1.5M | +$3.4M |
FENC's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
FENC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.5% | +1.6M shares |
| 1 year | +37% | +10.2M shares |
| 3 years | +43% | +11.5M shares |
| 5 years | +46% | +12.1M shares |
| Available history | +91% | +18.2M shares |
FENC has 38M diluted shares, up 37% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over FENC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
FENC Net Leverage
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
FENC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.6 | Neutral |
| Stochastic | 26.3 | Neutral |
FENC's weekly RSI is 56 (neutral) and its Stochastic is 26 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
FENC PE vs Healthcare Sector
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
FENC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.3 | 5.6% above |
| 20 week MA | $10.7 | 1.6% above |
| 50 week MA | $9.05 | 20% above |
| 100 week MA | $8.25 | 32% above |
| 200 week MA | $8.06 | 35% above |
FENC is in an uptrend: it's above all five of its weekly moving averages, and 35% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
FENC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.23 | $7.16 | +15% |
| 2021 | $7.16 | $4.49 | -37% |
| 2022 | $4.49 | $9.78 | +118% |
| 2023 | $9.78 | $11.2 | +15% |
| 2024 | $11.2 | $6.22 | -45% |
| 2025 | $6.22 | $8.09 | +30% |
| 2026 YTD | $8.09 | $10.9 | +35% |
FENC has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.